secwatch.observer — SEC 8-K summary ====================================== Issuer: Lakewood-Amedex Biotherapeutics Inc. (LABT) CIK: 0002079272 Form: 8-K Filed at: 2026-11-16T21:35:47+00:00 Accession: 0001213900-26-120724 Event type: regulatory Sentiment: negative Materiality: 0.82 Item codes: 3.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 Nasdaq to delist Lakewood-Amedex (LABT) after 30 days below $1.00; hearing sought -------------------------------------------------------------------------------- - Nov 10, 2026 Nasdaq staff letter: closing bid price stayed below $1.00 for 30 consecutive business days, Sept 29 through Nov 9, 2026. - Company is not eligible for a compliance cure period because it effected a 1-for-10 reverse stock split on June 22, 2026, within the prior year. - Unless a hearing is requested by Nov 17, 2026, trading is suspended at the open on Nov 19, 2026 and Nasdaq files Form 25-NSE to delist. - Company says it intends to timely request a Nasdaq Hearings Panel hearing, which would stay suspension, and may propose another reverse split. - Company warns no assurance the Panel grants continued listing or that it regains compliance with Rule 5550(a)(2). Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/2079272/000121390026120724/0001213900-26-120724-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/2079272/000121390026120724/ea0312471-8k_lakewood.htm HTML page: https://secwatch.observer/filing/0001213900-26-120724 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer